Physician profile
Ronald Mancini
NPI 1457307639
$832.51
in general payments reported to CMS, 2019-2025
6 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.21 · 2022: $170 · 2023: $150 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $378.65 | 2021-2023 | Tepezza |
| Biotissue Holdings INC. | $215.70 | 2025 | |
| Revance Therapeutics, INC. | $149.37 | 2025 | Daxxify |
| Amgen INC. | $38.47 | 2025 | Tepezza |
| Merz Pharmaceuticals, LLC | $34.85 | 2025 | Xeomin |
| Harrow Eye, LLC | $15.47 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mancini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.